Auris Medical Holding Ltd

EARS NASDAQ
2.840
-0.080
-2.74%
盘后: 2.800 -0.04 -1.41% 19:00 06/14 EDT
开盘
2.970
昨收
2.920
最高
3.050
最低
2.810
成交量
21.98万
成交均量(3M)
22.96万
52周最高
39.40
52周最低
2.410
换手率
0.91%
市值
6,837.98万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Auris Medical Holding Ltd EARS股票价格,Auris Medical Holding Ltd股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.
展开 >

最近浏览

名称
价格
涨跌幅